Short hairpin RNA attenuates liver fibrosis by regulating the PPAR‑γ and NF‑κB pathways in HBV‑induced liver fibrosis in mice

Ye,Lei; Chen,Ting; Cao,Jiaqi; Sun,Liying; Li,Wuping; Zhang,Chenghai

doi:10.3892/ijo.2020.5125

Short hairpin RNA attenuates liver fibrosis by regulating the PPAR‑γ and NF‑κB pathways in HBV‑induced liver fibrosis in mice

Authors:
- Lei Ye
- Ting Chen
- Jiaqi Cao
- Liying Sun
- Wuping Li
- Chenghai Zhang
View Affiliations

Affiliations: NHC Key Laboratory of Systems Biology of Pathogens (Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College), Beijing 100730, P.R. China, NHC Key Laboratory of Systems Biology of Pathogens (Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College), Beijing 100730, P.R. China, Shanghai Mabgeek Biotech. Co., Ltd., Shanghai 201203, P.R. China
Published online on: September 22, 2020 https://doi.org/10.3892/ijo.2020.5125
Pages: 1116-1128
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Progressive liver fibrosis, caused by chronic viral infection and metabolic disorders, results in the development of cirrhosis and hepatocellular carcinoma. However, no antifibrotic therapies have been approved to date. In our previous study, adeno‑associated virus (AAV) short hairpin RNAs (shRNAs) targeting hepatitis B virus (HBV) and transforming growth factor (TGF)‑β administration could persistently inhibit HBV replication and concomitantly prevent liver fibrosis. However, the differentially expressed proteins and critical regulatory networks of AAV‑shRNA treatment remain unclear. Accordingly, in the present study, we aimed to analyze differentially expressed proteins in the liver of AAV‑shRNA‑treated mice with HBV infection and liver fibrosis using isobaric tags for relative and absolute quantitation (iTRAQ)‑based quantitative proteomics and to elucidate the underlying antifibrotic mechanisms. In total 2,743 proteins were recognized by iTRAQ‑based quantitative proteomics analysis. Gene Ontology analysis revealed that the differentially expressed proteins mostly participated in peptide metabolism in the biological process category, cytosolic ribosomes in the cell component category, and structural constituents of ribosomes in the molecular function category. Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated that oxidative stress and the peroxisome proliferator‑activated receptor (PPAR) signaling pathway were activated after treatment. Verification studies revealed that AAV‑shRNAs inhibited hepatic stellate cell activation and inflammation by suppressing nuclear factor‑κB p65 phosphorylation and α‑smooth muscle actin expression via upregulation of PPAR‑γ. Hepatocytes steatosis was also decreased by activating the PPAR signaling pathway and improving lipid metabolism. The expression level of TGF‑β was decreased due to upregulation of PPAR‑γ expression and direct inhibition using AAV‑shRNA targeting TGF‑β. TGF‑β‑induced oxidative stress was suppressed by increasing glutathione S‑transferase Pi 1 and reducing peroxiredoxin 1. Collectively, the present results indicated that AAV‑shRNAs were effective in modulating liver fibrosis by reducing oxidative stress, inflammation and activating the PPAR signaling pathway.

View Figures

View References

1	Ringelhan M, Heikenwalder M and Protzer U: Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development. Dig Dis. 31:138–151. 2013. View Article : Google Scholar : PubMed/NCBI
2	McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology. 49(5 Suppl): S45–S55. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lin CL and Kao JH: Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 28:10–17. 2013. View Article : Google Scholar
4	Bonilla Guerrero R and Roberts LR: The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 42:760–777. 2005. View Article : Google Scholar : PubMed/NCBI
5	Karayiannis P: Hepatitis B virus: Virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 11:500–508. 2017. View Article : Google Scholar : PubMed/NCBI
6	Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, et al: A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 38:257–265. 2003. View Article : Google Scholar : PubMed/NCBI
7	Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011. View Article : Google Scholar
8	Alkofer B, Lepennec V and Chiche L: Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg. 148:3–11. 2011. View Article : Google Scholar : PubMed/NCBI
9	Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
10	Friedman SL, Roll FJ, Boyles J and Bissell DM: Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA. 82:8681–8685. 1985. View Article : Google Scholar : PubMed/NCBI
11	Senoo H, Mezaki Y and Fujiwara M: The stellate cell system (vitamin A-storing cell system). Anat Sci Int. 92:387–455. 2017. View Article : Google Scholar : PubMed/NCBI
12	Popov Y and Schuppan D: Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology. 50:1294–1306. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gressner AM, Weiskirchen R, Breitkopf K and Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci. 7:d793–d807. 2002. View Article : Google Scholar : PubMed/NCBI
14	Rahimi RA and Leof EB: TGF-beta signaling: A tale of two responses. J Cell Biochem. 102:593–608. 2007. View Article : Google Scholar : PubMed/NCBI
15	Shek FW and Benyon RC: How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol. 16:123–126. 2004. View Article : Google Scholar : PubMed/NCBI
16	Weidinger A and Kozlov AV: Biological activities of reactive oxygen and nitrogen species: Oxidative stress versus signal transduction. Biomolecules. 5:472–484. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kim YM and Cho M: Activation of NADPH oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa cells. Cell Signal. 26:784–796. 2014. View Article : Google Scholar : PubMed/NCBI
18	Schafer FQ and Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 30:1191–1212. 2001. View Article : Google Scholar : PubMed/NCBI
19	Dayer R, Fischer BB, Eggen RI and Lemaire SD: The peroxiredoxin and glutathione peroxidase families in Chlamydomonas reinhardtii. Genetics. 179:41–57. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gäbele E, Rusyn I, Yamashina S, Froh M, et al: The role of kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med. 31:1544–1549. 2001. View Article : Google Scholar : PubMed/NCBI
21	Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
22	Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G and Nimer SD: Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4:281–299. 1995.PubMed/NCBI
23	Dreyer C, Krey G, Keller H, Givel F, Helftenbein G and Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:879–887. 1992. View Article : Google Scholar : PubMed/NCBI
24	Xing G, Zhang L, Zhang L, Heynen T, Yoshikawa T, Smith M, Weiss S and Detera-Wadleigh S: Rat PPAR delta contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei. Biochem Biophys Res Commun. 217:1015–1025. 1995. View Article : Google Scholar : PubMed/NCBI
25	Chen F, Law SW and O'Malley BW: Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun. 196:671–677. 1993. View Article : Google Scholar : PubMed/NCBI
26	Xu J, Fu Y and Chen A: Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol. 285:G20–G30. 2003. View Article : Google Scholar : PubMed/NCBI
27	Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M and Evans RM: PPARγ signaling and metabolism: The good, the bad and the future. Nat Med. 19:557–566. 2013. View Article : Google Scholar : PubMed/NCBI
28	Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N and Geerts A: Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol. 47:142–156. 2007. View Article : Google Scholar : PubMed/NCBI
29	Zhao X, Xue J, Wang XL, Zhang Y, Deng M and Xie ML: Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. Int Immunopharmacol. 22:176–181. 2014. View Article : Google Scholar : PubMed/NCBI
30	Guo YT, Leng XS, Li T, Peng JR, Song SH, Xiong LF and Qin ZZ: Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells. World J Gastroenterol. 11:4735–4739. 2005. View Article : Google Scholar : PubMed/NCBI
31	Anty R and Lemoine M: Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 35(Suppl 1): S10–S20. 2011. View Article : Google Scholar : PubMed/NCBI
32	Sun K, Wang Q and Huang XH: PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin. 27:715–723. 2006. View Article : Google Scholar : PubMed/NCBI
33	Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA, Chen LZ, Harrington WW, Symonds WT and Rockey DC: Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 291:G902–G911. 2006. View Article : Google Scholar : PubMed/NCBI
34	Brasier AR: The NF-kappaB regulatory network. Cardiovasc Toxicol. 6:111–130. 2006. View Article : Google Scholar
35	Calzado MA, Bacher S and Schmitz ML: NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem. 14:367–376. 2007. View Article : Google Scholar : PubMed/NCBI
36	Luedde T and Schwabe RF: NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 8:108–118. 2011. View Article : Google Scholar : PubMed/NCBI
37	Kong D, Zhang F, Wei D, Zhu X, Zhang X, Chen L, Lu Y and Zheng S: Paeonol inhibits hepatic fibrogenesis via disrupting nuclear factor-κB pathway in activated stellate cells: In vivo and in vitro studies. J Gastroenterol Hepatol. 28:1223–1233. 2013. View Article : Google Scholar : PubMed/NCBI
38	Liu M, Wu Q, Chen P, Büchele B, Bian M, Dong S, Huang D, Ren C, Zhang Y, Hou X, et al: A boswellic acid-containing extract ameliorates schistosomiasis liver granuloma and fibrosis through regulating NF-κB signaling in mice. PLoS One. 9:e1001292014. View Article : Google Scholar
39	Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80. 2009. View Article : Google Scholar : PubMed/NCBI
40	Naugler WE and Karin M: The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 14:109–119. 2008. View Article : Google Scholar : PubMed/NCBI
41	Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J and Hellerbrand C: Lipid accumulation in hepato-cytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 19:996–1005. 2009. View Article : Google Scholar : PubMed/NCBI
42	Montiel-Duarte C, Ansorena E, López-Zabalza MJ, Cenarruzabeitia E and Iraburu MJ: Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine ('Ecstasy') on hepatic stellate cells. Biochem Pharmacol. 67:1025–1033. 2004. View Article : Google Scholar : PubMed/NCBI
43	Hernández E, Bucio L, Souza V, Escobar MC, Gómez-Quiroz LE, Farfán B, Kershenobich D and Gutiérrez-Ruiz MC: Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of Ikappabalpha degradation in liver stellate cells. Cell Biol Toxicol. 24:303–314. 2008. View Article : Google Scholar
44	Ye L, Kan F, Yan T, Cao J, Zhang L, Wu Z and Li W: Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice. Sci Rep. 7:38602017. View Article : Google Scholar
45	Kan F, Ye L, Yan T, Cao J, Zheng J and Li W: Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model. BMC Genomics. 18:6412017. View Article : Google Scholar : PubMed/NCBI
46	The Gene Ontology Consortium: The gene ontology resource: 20 Years and still GOing strong. Nucleic Acids Res. 47(D1): D330–D338. 2019. View Article : Google Scholar
47	Kanehisa M, Sato Y, Furumichi M, Morishima K and Tanabe M: New approach for understanding genome variations in KEGG. Nucleic Acids Res. 47(D1): D590–D595. 2019. View Article : Google Scholar :
48	Dillon ST, Bhasin MK, Feng X, Koh DW and Daoud SS: Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity. J Transl Med. 11:2392013. View Article : Google Scholar : PubMed/NCBI
49	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar
50	Yin L, Qi Y, Xu Y, Xu L, Han X, Tao X, Song S and Peng J: Dioscin inhibits HSC-T6 cell migration via adjusting SDC-4 expression: Insights from iTRAQ-based quantitative proteomics. Front Pharmacol. 8:6652017. View Article : Google Scholar : PubMed/NCBI
51	Wiese S, Reidegeld KA, Meyer HE and Warscheid B: Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. Proteomics. 7:340–350. 2007. View Article : Google Scholar
52	Ye L, Yu H, Li C, Hirsch ML, Zhang L, Samulski RJ, Li W and Liu Z: Adeno-associated virus vector mediated delivery of the HBV genome induces chronic hepatitis B virus infection and liver fibrosis in mice. PLoS One. 10:e01300522015. View Article : Google Scholar : PubMed/NCBI
53	Wang X, Li Y, Xu G, Liu M, Xue L, Liu L, Hu S, Zhang Y, Nie Y, Liang S, et al: Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. BMC Cancer. 15:3582015. View Article : Google Scholar : PubMed/NCBI
54	Gan CS, Chong PK, Pham TK and Wright PC: Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res. 6:821–827. 2007. View Article : Google Scholar : PubMed/NCBI
55	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium Nat Genet. 25:25–29. 2000.
56	Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev. 20:649–688. 1999.PubMed/NCBI
57	Venook AP, Papandreou C, Furuse J and de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist. 15(Suppl 4): S5–S13. 2010. View Article : Google Scholar
58	Wang D, Cai H, Yu WB and Yu L: Identification of hepatitis B virus X gene variants between hepatocellular carcinoma tissues and pericarcinoma liver tissues in Eastern China. Int J Clin Exp Pathol. 7:5988–5996. 2014.PubMed/NCBI
59	Ringelhan M, O'Connor T, Protzer U and Heikenwalder M: The direct and indirect roles of HBV in liver cancer: Prospective markers for HCC screening and potential therapeutic targets. J Pathol. 235:355–367. 2015. View Article : Google Scholar
60	Atta HM: Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol. 21:5138–5148. 2015. View Article : Google Scholar : PubMed/NCBI
61	Li T, Zhao XP, Wang LY, Gao S, Zhao J, Fan YC and Wang K: Glutathione S-transferase P1 correlated with oxidative stress in hepatocellular carcinoma. Int J Med Sci. 10:683–690. 2013. View Article : Google Scholar : PubMed/NCBI
62	Ding C, Fan X and Wu G: Peroxiredoxin 1-an antioxidant enzyme in cancer. J Cell Mol Med. 21:193–202. 2017. View Article : Google Scholar
63	Ginguay A, Cynober L, Curis E and Nicolis I: Ornithine amino-transferase, an important glutamate-metabolizing enzyme at the crossroads of multiple metabolic pathways. Biology (Basel). 6:182017.
64	Chávez E, Castro-Sánchez L, Shibayama M, Tsutsumi V, Moreno MG and Muriel P: Sulfasalazine prevents the increase in TGF-β, COX-2, nuclear NFκB translocation and fibrosis in CCl4-induced liver cirrhosis in the rat. Hum Exp Toxicol. 31:913–920. 2012. View Article : Google Scholar
65	Bitencourt S, de Mesquita FC, Caberlon E, da Silva GV, Basso BS, Ferreira GA and de Oliveira JR: Capsaicin induces de-differentiation of activated hepatic stellate cell. Biochem Cell Biol. 90:683–690. 2012. View Article : Google Scholar : PubMed/NCBI
66	Rhee SG, Chae HZ and Kim K: Peroxiredoxins: A historical over-view and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
67	Halliwell B: Oxidative stress and cancer: Have we moved forward? Biochem J. 401:1–11. 2007. View Article : Google Scholar
68	Reza JZ, Doosti M, Salehipour M, Packnejad M, Mojarrad M and Heidari M: Modulation peroxisome proliferators activated receptor alpha (PPAR alpha) and acyl coenzyme A: Cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell. Lipids Health Dis. 8:382009. View Article : Google Scholar : PubMed/NCBI
69	Guo Y, Jolly RA, Halstead BW, Baker TK, Stutz JP, Huffman M, Calley JN, West A, Gao H, Searfoss GH, et al: Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes. Toxicol Sci. 96:294–309. 2007. View Article : Google Scholar : PubMed/NCBI
70	van der Leij FR, Bloks VW, Grefhorst A, Hoekstra J, Gerding A, Kooi K, Gerbens F, te Meerman G and Kuipers F: Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics. 90:680–689. 2007. View Article : Google Scholar : PubMed/NCBI
71	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
72	Murai S, Ando A, Ebara S, Hirayama M, Satomi Y and Hara T: Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions. Oncogenesis. 6:e3292017. View Article : Google Scholar : PubMed/NCBI
73	Wang G, Bonkovsky HL, de Lemos A and Burczynski FJ: Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res. 56:2238–2247. 2015. View Article : Google Scholar : PubMed/NCBI
74	Wu YL, Peng XE, Zhu YB, Yan XL, Chen WN and Lin X: Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J Virol. 90:1729–1740. 2016. View Article : Google Scholar :
75	Mukai T, Egawa M, Takeuchi T, Yamashita H and Kusudo T: Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS Open Bio. 7:1009–1016. 2017. View Article : Google Scholar : PubMed/NCBI
76	Wolfrum C, Buhlmann C, Rolf B, Börchers T and Spener F: Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim Biophys Acta. 1437:194–201. 1999. View Article : Google Scholar : PubMed/NCBI